Arrowhead Pharmaceuticals (ARWR) to Release Quarterly Earnings on Thursday

Arrowhead Pharmaceuticals (NASDAQ:ARWR) is projected to issue its Q1 2026 results after the market closes on Thursday, February 5th. Analysts expect the company to announce earnings of $0.82 per share and revenue of $225.6580 million for the quarter. Individuals may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Thursday, February 5, 2026 at 4:30 PM ET.

Arrowhead Pharmaceuticals Trading Down 2.0%

Shares of ARWR stock opened at $65.58 on Thursday. The firm has a fifty day moving average price of $64.01 and a 200-day moving average price of $41.11. The company has a market cap of $8.91 billion, a price-to-earnings ratio of -819.65 and a beta of 1.21. Arrowhead Pharmaceuticals has a 1 year low of $9.57 and a 1 year high of $76.76. The company has a debt-to-equity ratio of 0.43, a current ratio of 4.86 and a quick ratio of 4.86.

Analyst Ratings Changes

Several brokerages recently commented on ARWR. Morgan Stanley increased their price objective on shares of Arrowhead Pharmaceuticals from $48.00 to $81.00 and gave the company an “equal weight” rating in a research report on Wednesday, January 7th. Piper Sandler reissued an “overweight” rating and set a $110.00 price target (up previously from $100.00) on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, January 13th. HC Wainwright upped their price objective on shares of Arrowhead Pharmaceuticals from $85.00 to $100.00 and gave the stock a “buy” rating in a report on Wednesday, January 21st. The Goldman Sachs Group lifted their price objective on Arrowhead Pharmaceuticals from $50.00 to $85.00 and gave the company a “neutral” rating in a research note on Wednesday, January 7th. Finally, Bank of America increased their target price on shares of Arrowhead Pharmaceuticals from $62.00 to $81.00 and gave the company a “buy” rating in a research report on Tuesday, December 9th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $81.67.

Insider Activity

In other news, COO Patrick O’brien sold 49,493 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $63.11, for a total value of $3,123,503.23. Following the transaction, the chief operating officer directly owned 474,908 shares of the company’s stock, valued at $29,971,443.88. This trade represents a 9.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Mauro Ferrari sold 7,530 shares of the business’s stock in a transaction on Friday, December 26th. The shares were sold at an average price of $70.00, for a total transaction of $527,100.00. Following the transaction, the director owned 69,053 shares in the company, valued at approximately $4,833,710. This represents a 9.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 510,836 shares of company stock worth $33,603,060 over the last quarter. Corporate insiders own 4.30% of the company’s stock.

Institutional Trading of Arrowhead Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in ARWR. iSAM Funds UK Ltd acquired a new position in Arrowhead Pharmaceuticals during the 3rd quarter worth approximately $29,000. Daiwa Securities Group Inc. grew its holdings in shares of Arrowhead Pharmaceuticals by 883.3% in the second quarter. Daiwa Securities Group Inc. now owns 4,189 shares of the biotechnology company’s stock valued at $66,000 after acquiring an additional 3,763 shares in the last quarter. Lazard Asset Management LLC purchased a new stake in shares of Arrowhead Pharmaceuticals during the 2nd quarter valued at $91,000. Quadrant Capital Group LLC purchased a new stake in Arrowhead Pharmaceuticals during the third quarter worth about $140,000. Finally, State of Wyoming bought a new stake in shares of Arrowhead Pharmaceuticals in the 2nd quarter worth approximately $142,000. Institutional investors and hedge funds own 62.61% of the company’s stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.